Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 19, 2024
Discovery & Translation

Science Spotlight: Platelets as targeted protein degraders 

BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | May 31, 2024
Distillery Therapeutics

Armored, iPSC-derived CAR macrophages for pancreatic cancer

BioCentury | Apr 25, 2023
Discovery & Translation

Prime and base editing for blood disorders, mutation tracing for NASH target discovery and more

BioCentury’s roundup of translational news
BioCentury | Apr 1, 2023
Discovery & Translation

A bacterial injection system for protein delivery, base editing for CD3δ SCID and more

BioCentury’s roundup of translational news
BioCentury | Oct 21, 2022
Politics, Policy & Law

Oct. 20 Quick Takes: Novartis commits first cancer therapy to UN patent pool

Plus: AbbVie gains LPAR1 antibody via $255M buy of DJS and updates for Denali, the U.K., Kite-Refuge, Takeda-Zedira, Immunic, Talaris, Celeris
BioCentury | Sep 6, 2022
Distillery Therapeutics

Blocking PRMT7 to target leukemia stem cells in CML

BioCentury | Aug 26, 2022
Discovery & Translation

Detecting Parkinson’s via breathing signals; plus Antisense, Noster and more

BioCentury’s roundup of translational news
BioCentury | Oct 7, 2021
Product Development

Fabry disease’s five-year prospects look up

Comparing the profiles of up-and-coming therapies for Fabry disease
BioCentury | Sep 30, 2021
Product Development

Gaucher disease pipeline: Data Byte

Three clinical and 11 preclinical candidates move beyond traditional enzyme replacement, aim for wider range of patients
Items per page:
1 - 10 of 305
Help Center
Username
Request a Demo
Request Training
Ask a Question